The Board of Directors of Vijaya Diagnostic Centre Limited, in their meeting held on February 13, 2026, approved the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. For the quarter ended December 31, 2025, the company reported a consolidated revenue of ₹214.35 Crores, representing a 6.34% growth compared to the previous quarter (QoQ) and a 26.83% increase compared to the same quarter last year (YoY). The net profit for the current quarter stood at ₹46.12 Crores, which is a 6.56% increase from the previous quarter and a substantial 77.38% jump from the corresponding quarter of the previous year. Alongside the results, the Board approved the appointment of Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola as additional Non-Executive-Independent Directors for a five-year term, effective February 13, 2026, subject to shareholder approval.

Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India, providing a comprehensive range of pathology and radiology services. As of 2025, the company operates approximately 200 diagnostic centres and over 15 NABL-accredited laboratories across 25+ cities in six Indian states, including Telangana, Andhra Pradesh, and West Bengal. In October 2025, the company received final approval from the National Company Law Tribunal (NCLT) for the merger of Medinova Diagnostic Services Limited into Vijaya Diagnostic Centre, a strategic move aimed at enhancing operational efficiencies and expanding its market footprint. The company continues to focus on a B2C-dominant business model, which contributes approximately 93% of its revenue. Prominent institutional investors in the company include the HSBC Small Cap Fund, Aberdeen New India Investment Trust, and Motilal Oswal Small Cap Fund, with mutual funds collectively holding nearly 28% of the equity as of December 2025.